



NASDAQ: QTI

# Transforming Breast Health Through Imaging Intelligence

## Snapshot

QT Imaging is redefining breast imaging with the **first FDA cleared quantitative breast imaging platform**, combining anatomical and functional imaging through quantitative transmission and reflection ultrasound. The Company is building a scalable **3D platform for dense breast diagnostics and precision oncology**, delivering AI and biomarker driven imaging without radiation, compression, or contrast agents, supported by a newly awarded AMA Category III CPT code.

**QT Imaging is evolving beyond hardware into a data driven imaging platform** that continuously improves through clinical use, quantitative biomarkers, and AI enabled learning.

### The business model combines:

- **FDA cleared QT Breast Acoustic CT™ imaging platform with an AMA awarded Category III CPT code effective January 1, 2027**, establishing the first dedicated reimbursement milestone for QT Imaging technology
- **Advanced image reconstruction and multi-modality visualization software**
- **Quantitative imaging biomarkers** including speed of sound, fibroglandular ratio (breast density), attenuation, reflection, and additional tissue characterization parameters
- **QTI Precision Pathway cloud ecosystem, including scanner evergreen, biomarker analytics, and enterprise collaboration tools** delivered through a layered SaaS model with continuous updates and minimal on site installation burden

## The Problem

### Current Standard of Care Challenges

- **Dense Breast Limitations:** Mammography misses ~35–52% of cancers in dense breast tissue<sup>(1)</sup>
- **Low Compliance:** 35% of women avoid regular breast screening<sup>(2)</sup>
- **High Recall Rates:** ~10-15% mammography callback rate; most recalls do not result in cancer diagnosis<sup>(3)</sup>
- **Unnecessary Biopsies:** >80% of biopsies following screening callbacks are benign<sup>(4)</sup>
- **MRI Limitations:** Expensive, contrast based, and capacity constrained
- **Ultrasound Limitations:** Operator dependent and variable
- **Fragmented Workflow:** Multiple tests and disconnected care pathways

(1) DenseBreast-info / NIH (2) CDC (3) American Cancer Society (4) NIH / PubMed

## The QT Imaging Solution

### Quantitative Transmission Imaging

- **Differentiated Platform:** First FDA cleared quantitative breast imaging platform combining anatomic and functional imaging with quantitative transmission ultrasound
- **True 3D Volumetric Imaging:** Generates a unique 3D quantitative dataset for biomarker driven cancer detection and characterization
- **MRI-like Resolution:** Achieved without contrast agents and without the enclosed environment associated with MRI
- **Dense Breast Solution:** Designed for improved assessment in dense breasts where mammography performance declines
- **Safe & Comfortable:** Pain free imaging with no radiation, breast compression, or contrast injection
- **Consistent & Standardized Imaging:** Overcomes operator dependence and lack of standardization seen with handheld ultrasound
- **Reimbursement Derisking:** AMA awarded Category III CPT code supporting future adoption pathway
- **Commercial Ready:** Active commercial engine with international expansion and established distribution infrastructure
- **QTI Precision Pathway – Cloud Platform Expansion:** AI, biomarkers, cloud SaaS, and precision oncology applications support future growth

# QT Imaging Value Proposition

This is one of the rare cases where patients, clinicians, and providers all win:



## For the Patient

- One-stop supplemental and diagnostic breast imaging
- **No radiation, breast compression, or contrast injection**
- **Safe and comfortable imaging experience**
- **Lower recalls** and reduced patient anxiety
- **Operator independent** imaging



## For the Clinician

- **One test, multiple outputs:** MRI like imaging, breast density, cyst / solid characterization, implant imaging, lesion doubling assessment, and quantitative biomarkers
- Unique fully **3D quantitative dataset enabling biomarkers** including speed of sound, attenuation, reflection, and breast density (FGR)
- Potential to **reduce unnecessary biopsies**
- **Standardized, operator independent** imaging workflow



## For the Administrator



- **One-stop imaging workflow** with future cloud, AI, and biomarker revenue expansion
- **2.5 X more revenue per scan** compared to mammography + handheld ultrasound
- **30% less annual labor cost** – nonspecialized personnel
- Attractive economics and investment recovery - **3-year investment recovery with 5 patients/day**

## Clinical Validation Across Screening and Oncology Applications:

### Mayo Clinic | QTscan vs MRI

- **Mayo Clinic prospective feasibility study:** 26 high-risk women comparing QT Imaging (QTscan) with breast MRI for supplemental screening
- **Strong breast-level agreement with MRI:** binary agreement between QTscan and MRI across 52 breasts
- **Comparable detection profile**
- **All MRI-suspicious lesions were identified by QTscan**

This QT Imaging Mayo Clinic pilot provides strong clinical validation and supports larger studies aimed at **expanding QT Imaging adoption in high-risk and supplemental screening.**



## Regulatory and Reimbursement Progress

- **FDA clearance** in place
- **AMA Category III CPT code (X579T)** approved in February 2026 with effective date January 1, 2027
- Reimbursement pathway advancing with Category III CPT implementation and **future biomarker / SaaS coding expansion opportunities**
- **UAE MOHAP** clearance in place
- **Saudi FDA** clearance in place
- **AMAR Israel** regulatory approval anticipated in Q4'26
- **CE Mark** regulatory approval targeted in 2027



# Commercial Momentum and Revenue Growth

- Q1 2026 revenue reached **\$6.5M**, up **133%** year-over-year; 2025 revenue was **\$18.9M**, up **288%** versus 2024
- 13 scanners shipped in Q1 2026, building upon **40 scanners shipped** in 2025
- **Revenue guidance for 2026 of approx. \$39M**, based on contracted revenue from NXC Imaging (subsidiary of Canon Medical Systems) in the U.S., Gulf Medical in Saudi Arabia and Al Naghi Medical in the UAE
- Relisted on **Nasdaq** and included in **Russell Microcap**

**Index**, expanding institutional visibility

- Raised **\$10M** to fund commercial, clinical, and strategic growth initiatives
- Extended senior term loan maturity by two years, to March 31, 2029
- **QTI Precision Pathway** expansion supports recurring software and cloud revenue
- Enhanced clinical leadership with **Dr. Mary Yamashita** and **Dr. Barry Roseman** supporting clinical validation, physician adoption, and commercialization




## Investment Highlights

- **FDA cleared quantitative breast imaging platform** AMA Category III CPT reimbursement code awarded
- **Safe, radiation free, compression free** imaging with MRI like resolution and no contrast injection
- Unique fully **3D quantitative imaging dataset enabling biomarkers, AI, and precision diagnostics**
- Relisted on **Nasdaq** in January 2026 and included in the **Russell Microcap Index**
- Strong balance sheet following recent **\$10M financing**,

supporting commercialization and platform expansion

- **Commercial engine active** with international expansion underway
- **QTI Precision Pathway** cloud SaaS platform supporting recurring revenue expansion
- **Clinical validation** supported by leading institutions and world class KOLs in breast imaging, radiology, and oncology
- **Platform expansion opportunity** across biomarkers, AI, cloud workflows, and precision oncology applications

## QTI Precision Pathway Cloud SaaS Platform

	Core	Operational	Advanced	Enterprise
	System software updates Long term technology relevance	Collaboration & data sharing	Quantitated biomarkers Automated analysis Precision reporting	Multuser access Enterprise collaboration
 Biomarker / Analysis			✓	✓
 QTI Precision Share		✓	✓	✓
 Scanner Evergreen	✓	✓	✓	✓

**Platform upside – AI/Biomarkers, additional reimbursement codes**

DISCLAIMER: This information is published solely for informational purposes, does not purport to be all-inclusive, and is not to be construed as a solicitation or an offer to sell any security. The summary may include "forward-looking statements" with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934 and are intended to be covered by the safe harbor provisions for forward looking state-ments. These forward-looking statements are subject to a number of risks and uncertainties as described in our filings with the SEC. This information is supplied from sources we believe to be reliable, but we cannot guarantee accuracy. This document has been furnished to you solely for your information. Any company names or logos of other companies are the trademarks and/or intellectual property of those other companies, and their use is not intended to, and does not imply, a relationship with QT Imaging Holdings, Inc. or an endorsement or sponsorship by or of QT Imaging Holdings, Inc.

### Contact Us:

**Investors:** Tirth Patel · tirth@coreir.com  
**Media:** Matthew Cossel · matthewwc@coreir.com

Three Hamilton Landing, Suite 160, Novato, CA 94949  
[www.QTIImaging.com](http://www.QTIImaging.com)